Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Fluticasone Propionate · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | PLACEBO_COMPARATOR | - |
| Ibuprofen | EXPERIMENTAL | - |
| Fluticasone propionate | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Fluticasone Propionate | DRUG | Dry powder for inhalation, Single Dose, 500mcg |
| Placebo for Fluticasone Propionate | DRUG | Dry powder for inhalation, Single Dose, placebo |
| Ibuprofen | DRUG | 800 mg oral |
| Placebo | DRUG | Placebo |
Inclusion Criteria: * Healthy volunteers * Normoresponsive airways - histamine PC20\>16mg/mL * Able to complete sputum induction successfully Exclusion Criteria: * Non (or ex) smokers * No LPS challenge in previous 4 weeks
Fluticasone Propionate is a small molecule being studied for allergic rhinitis and chronic obstructive pulmonary disease. In clinical trials, it has been evaluated for its effects on inflammatory markers after nasal allergen challenge in seasonal allergic rhinitis and on sputum neutrophils after inhaled lipopolysaccharide challenge in chronic obstructive pulmonary disease.
Fluticasone Propionate is being developed by Pfizer, Inc., which trades under the ticker PFE. The company is conducting clinical research on the drug for respiratory conditions.
Fluticasone Propionate is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The completed Phase 1 trials were designed to explore its effects on inflammatory responses in allergic rhinitis and chronic obstructive pulmonary disease.
Fluticasone Propionate has been studied in two completed Phase 1 trials. NCT01064726 examined its effect on inflammatory markers after nasal allergen challenge in 18 participants with seasonal allergic rhinitis in the United States. NCT01364519 evaluated its effect on sputum neutrophils after inhaled lipopolysaccharide challenge in 17 volunteers in the United Kingdom.
Fluticasone Propionate is the active ingredient in Flonase, a nasal spray used for allergies. In the clinical trials listed, it was administered as a single dose to study its effects on allergic rhinitis and chronic obstructive pulmonary disease. The drug is being developed by Pfizer for respiratory conditions.